Vivos Therapeutics, Inc. Files Amendment No. 1 to S-1 Registration Statement

TL;DR

<b>Vivos Therapeutics, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities.</b>

AI Summary

Vivos Therapeutics, Inc. (VVOS) filed a Amended IPO Registration (S-1/A) with the SEC on April 22, 2024. Vivos Therapeutics, Inc. filed an amendment (No. 1) to its Form S-1 Registration Statement on April 22, 2024. The filing relates to the registration of securities under the Securities Act of 1933. The company's principal executive offices are located at 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120. The company was formerly known as Vivos BioTechnologies, Inc., with a name change effective September 1, 2017. Vivos Therapeutics, Inc. is classified as a smaller reporting company and an emerging growth company.

Why It Matters

For investors and stakeholders tracking Vivos Therapeutics, Inc., this filing contains several important signals. This amendment suggests the company is actively pursuing a public offering or other securities-related transactions, which could impact its capital structure and shareholder base. As a smaller reporting and emerging growth company, Vivos Therapeutics may be subject to different regulatory requirements and disclosure obligations compared to larger, more established firms.

Risk Assessment

Risk Level: low — Vivos Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies seeking to offer securities, and does not inherently indicate significant new risks.

Analyst Insight

Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 1 — Amendment Number (Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT)
• 1933 — Securities Act Year (SECURITIES ACT OF 1933)
• 20170901 — Date of Name Change (DATE OF NAME CHANGE: 20170901)
• 80120 — ZIP Code (Littleton, Colorado 80120)

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• Vivos BioTechnologies, Inc. (company) — Former company name
• R. Kirk Huntsman (person) — Chairman of the Board and Chief Executive Officer
• Barry I. Grossman (person) — Counsel
• Lawrence A. Rosenbloom (person) — Counsel
• Ellenoff Grossman & Schole LLP (company) — Legal counsel
• 333-278564 (regulator) — SEC File Number
• 2024-04-22T00:00:00.000Z (date) — Filing date

FAQ

Industry Context

The filing is related to the medical instruments and apparatus industry (SIC 3841), specifically concerning the registration of securities for a public offering.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of new securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track subsequent SEC filings for updates on the registration effectiveness and offering progress.
3. Analyze the company's financial health and business strategy in conjunction with the offering details.

Key Dates

• 2024-04-22T00:00:00.000Z: Filing of Amendment No. 1 to Form S-1 — Indicates ongoing securities registration process.
• 2017-09-01T00:00:00.000Z: Company Name Change — Vivos Therapeutics, Inc. was formerly Vivos BioTechnologies, Inc.

Year-Over-Year Comparison

This is an amendment to a previously filed S-1 registration statement, indicating a continuation or modification of the initial filing.

Key Financial Figures

• $0.0001 — 7,259 shares of common stock, par value $0.0001 per share (or the Common Stock), of Viv
• $3.01 — common stock as reported on Nasdaq was $3.01 per share. We are an &ldquo;emerging
• $8,000,000 — ch we agreed sell up to an aggregate of $8,000,000 of securities of the Company of units.
• $30 — iated Common Stock Purchase Warrant was $30.00, and the purchase price per Pre-Fund
• $29.9998 — iated Common Stock Purchase Warrant was $29.9998. We are registering the warrant shares
• $4,000,003.44 — rsuant to which we sold an aggregate of $4,000,003.44 of securities in a private placement co
• $3.83 — Common Stock with an exercise price of $3.83 per share and (iii) an 18-month Series

Filing Documents

• forms-1a.htm (S-1/A) — 421KB
• ex23-1.htm (EX-23.1) — 4KB
• ex23-2.htm (EX-23.2) — 4KB
• forms-1_001.jpg (GRAPHIC) — 7KB
• 0001493152-24-015414.txt (&nbsp;) — 440KB

From the Filing

filed with the U.S. Securities and Exchange Commission on April 19, 2024 Registration No. 333-278564 UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 8011 81-3224056 (State or jurisdiction of incorporation or organization) (Primary (IRS Employer Identification No.) 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 (844) 672-4357 (Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices) R. Kirk Huntsman Chairman of the Board and Chief Executive Officer Vivos Therapeutics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 (844) 672-4357 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Barry I. Grossman, Esq. Lawrence A. Rosenbloom, Esq. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, New York 10105 Telephone: (212) 370-1300 Approximate date of commencement of proposed sale to the public : As soon as practicable after the effective date of this Registration Statement. If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), acting pursuant to said Section 8(a), may determine. EXPLANATORY NOTE This Amendment No. 1 on Form S-1/A (&ldquo;Amendment No. 1&rdquo;) to the Registration Statement on Form S-1 of Vivos Therapeutics, Inc., originally filed with the Securities and Exchange Commission on April 9, 2024 (the &ldquo;Original Filing&rdquo;), is being filed solely to update the Incorporation of Certain Information by Reference section herein. Except for the foregoing amended information, this Amendment No. 1 does not amend or update any other information contained in the Original Filing, nor does it reflect any events that have occurred after the filing date of the Original Filing. The information in this prospectus is not complete and may be changed. The securities in this registration statement may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. PRELIMINARY PROSPECTUS 1,737,259 shares common stock This prospectus relates to the offer for sale of up to an aggregate of 1,737,259 shares of common stock, par value $0.0001 per share (or the Common Stock), of Vivos Therapeutics, Inc. by the selling stockholder named herein (who we refer to as the selling stockholder), which is comprised of: (i) 266,667 shares of Common Stock underlying a common stock purchase warrant issued to the selling

View Full Filing

View this S-1/A filing on SEC EDGAR